cancer biosimilars

Views & Analysis

Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.

News

Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.